Strides Arcolab has announced its financial results for the quarter ended June 30, 2013. The consolidated pharma revenues in H1’13 has been reported at Rs 464 crores with an EBITDA of Rs101 crores, impacted by an exchange loss of Rs 15 crores (EBITDA margin of 22 per cent). Adjusted for exchange loss, the H1’13 EBITDA has been reported at Rs 116 crores and EBITDA margin of 25 per cent. The pharma business EBITDA is in line with guidance for 2013 (Revenue guided at Rs 1000 crores with an EBITDA of Rs 200 crores).
In Q2’13 the consolidated pharma revenues has been reported at Rs 228 crores with an EBITDA of Rs.41 crores, impacted by an exchange loss of Rs 15 crores (EBITDA margin of 18 per cent). In Q2’13 the consolidated pharma EBITDA grew by 30 per cent (Rs 41 crores in Q2 2013 against Rs .31 crores in Q2 2012).
Arun Kumar, Vice Chairman and Group Chief Executive Officer, Strides Arcolab.“We are pleased with our performance which is in line with our guided EBITDA and revenues. With recent product approvals, we expect to deliver a strong second half in our pharma business.”
EP News Bureau – Mumbai
